An Observational Study To Assess The Clinical Changes Of Topical Cyclosporine 0.05 percent Ophthalmic Solution In The Management Of Mild To Moderate Dry Eye Disease

Dry eye syndrome (DES) is a multifactorial disease of the ocular surface with tear film abnormalities, leading to eye discomfort, visual disturbance, tear film instability, and inflammation of the ocular surface.1 DES accounts for as many as 17%-25% of visits to ophthalmology clinics making it one of the most common ocular conditions. Patients with uncontrolled and chronic DES are at risk for ocular infections however, due to the natural defence mechanisms of the eye, overt intraocular infections are relatively uncommon.

Traditional therapies for DES mainly focus on the lubrication of the ocular surface with artificial tears. However, these treatments do not address the underlying ocular surface inflammation. Cyclosporine, an immunomodulatory agent, has been shown to block T-cell proliferation and receptor signal transduction. The cell-mediated inflammatory responses are modulated through the downregulation of IL-2 receptor expression and gene transcription.Because of the properties noted above, topical cyclosporine eye drops are indicated for the treatment of DES.